Patent ID: 6034099
Filing Date: 2000-03-07
Classification: A61K

Abstract:
A method of treating a mammal having precancerous lesions comprising administering a pharmacologically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof:wherein R.sub.1 is tetrazolyl- or phosphonyl-substituted phenyl, pyridyl, or a substituted or unsubstituted benzyl, phenyl, or 1-3 carbon alkyl chain alkoxybenzyl wherein said substituents on said benzyl, phenyl or alkoxybenzyl are one to three selected from the group consisting of amino, acyl, halogen, nitro, CN, AO--, carboxyl, sulfonyl, A--O--CO, A--CO--NH--, A--CO--NA--, carbamoyl, N-alkylcarbamoyl, 1-6 carbon alkyl chain N,N-dialkylcarbamoyl, A--O--CO--NH--, A--O--CO--NA--, R.sub.4 NSO.sub.2 R.sub.5 and SO.sub.2 NR.sub.4 R.sub.5 ;R.sub.2 is selected from the group consisting of C.sub.1-5 alkyl alkoxycarbonylalkyl, hydroxyalkyl and hydroxycarbonylalkyl;R.sub.3 is hydrogen, C.sub.1-5 alkyl, C.sub.1-5 alkoxy, halo-substituted alkyl, aminoalkanoyl, aminoalkyl, carbamoyl or SO.sub.2 NR.sub.4 R.sub.5 ;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6 alkyl, or --NR.sub.4 R.sub.5 together form a 5 or 6 membered ring optionally containing other heteroatoms selected from the group consisting of N, S, O, and the ring can be optionally substituted by A, A--CO--NH--SO.sub.2 --, A--CO--NA--SO.sub.2, A--SO.sub.2 --NH--, A--SO.sub.2 --NA--, (A--SO.sub.2).sub.2 N--; andA is C.sub.1-6 alkyl or C.sub.1-6 haloalkyl and physiologically acceptable salts thereof.